Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis

Published:2021-11 Issue: Volume:360 Page:577721
ISSN:0165-5728
Container-title:Journal of Neuroimmunology
language:en
Short-container-title:Journal of Neuroimmunology

Author:

Sriwastava Shitiz,Kataria Saurabh,Srivastava Samiksha,Kazemlou Shaghayegh,Gao Si,Wen Sijin,Saber Hamidreza,Tripathi Richa,Sheikh Zubeda,Peterson Sarah,Gwinn Ronald,Bernitsas Evanthia

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,Immunology,Immunology and Allergy

Reference48 articles.

1. Immunosenescence and its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention;Aiello;Front. Immunol.,2019

2. Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate;Baharnoori;Neurology(R) Neuroimmunol. Neuroinflammation,2016

3. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section;Berger;Neurology,2013

4. Progressive multifocal leukoencephalopathy after fingolimod treatment;Berger;Neurology.,2018

5. Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review;Bohra;Cancer Control,2017

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An update on managing patients with multiple sclerosis in primary care;JAAPA;2024-02

2. A Case of Primary Central Nervous System Lymphoma That Developed in a Patient Receiving Fingolimod Therapy for Multiple Sclerosis;Cureus;2023-12-26

3. Current and Future Developments in Imaging and Treatment of White Matter Disease: A Systematic Review;Cureus;2023-12-24

4. A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis;Multiple Sclerosis Journal;2023-12-22

5. From Animal Models to Clinical Trials: The Potential of Antimicrobials in Multiple Sclerosis Treatment;Biomedicines;2023-11-16